|
ICU & Emergency Medicine Product Line
When bleeding emergencies arise, urgent surgery is required, sepsis has taken hold, or multi-factor coagulation deficiencies are discovered, you require treatment options that work under the pressure you do to achieve fast and effective restoration of the body’s natural balance. Octapharma’s ICU product line has demonstrated excellent efficacy and tolerability in the treatment of this critical patient group. With so many variables to control, the ability to rely on your treatment options is essential.
Click here to review general information about the indications for the ICU & Emergency Medicine Product Line.
 |
|
|
| octaplas® - Pharmaceutically licensed, SD treated plasma for transfusion. With more than 5’500’000 units used, octaplas® has demonstrated to avoid TRALI and reduce adverse reactions, setting new standards in Transfusion Medicine. Available in 200ml bags in A, B, O and AB blood groups. |
|
|
|
|
|
|
|
|
|
 |
|
|
octaplex® - Octapharma’s state-of-the-art human prothrombin complex concentrate. octaplex® offers a good haemostatic balance of coagulation factors and inhibitors, with a fast on set of action and minimal thrombogenic risk. (Sold in Sweden under the registered name ocplex® and in Australia as
Pronativ®.) |
|
|
|
|
|
|
|
|
|
 |
|
|
| atenativ® - High purity antithrombin concentrate for the treatment of coagulation disturbances in connection with inherited and acquired antithrombin deficiency. atenativ® is double virus-inactivated by a combination of SD and heated treatment and, is the only heparin free marketed antithrombin. Available in 500 IU and 1000 IU vial. |
|
|
|
|
|
|
|
|
|
 |
|
|
|
albumin 5% albumin 20%, albumin 25% - Human protein solution, with low aluminium content, for the restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated.
|
|
|
|
|
|
|
|
|
|
Octapharma supports the development and education of best practice through continual clinical research, cooperation’s with industry associations, and regular educational symposiums. Octapharma works with the Plasma Protein Therapeutics Association to provide balanced and scientifically based evidence on the unique biochemical properties and appropriate clinical utilization of albumin. Twice a year, Octapharma hosts educational sessions involving international leaders in sepsis and disseminated intravascular coagulopathy research in Denmark.
|
|
 |
|
|
